Victoza dosage: what the label actually says

Who does the label cover, and who does it not?

Patients aged 10 and older with type 2 diabetes are covered, on 0.6 mg steps at least a week apart, up to the same 1.8 mg ceiling adults have. The label says the risk of low blood sugar ran higher in this age group whatever else they were taking. Nothing is established below age 10.

The Victoza label does not cover weight loss. It also says that taking it alongside another liraglutide product is not recommended, which rules out running it with Saxenda.

What if a week gets missed?

The label answers this differently from the weekly products. A missed day is skipped: take the next scheduled dose, and do not add one or raise it to catch up. Past 3 days without a dose, the label says to restart at 0.6 mg and climb again.

What does it come in?

The device matters for dosing, because some of these hold one dose and some hold four.

Victoza and Saxenda are the same drug. So why are the doses different?

Saxenda is the same drug substance from the same manufacturer, approved for weight rather than blood sugar, and its label runs to 3 mg a day where this one stops at 1.8 mg.

Both products contain liraglutide, and both come from Novo Nordisk. They were approved under separate applications, NDA 022341 and NDA 206321, for different groups of people. A separate application means a separate schedule, a separate top dose and a separate rule for a missed week.

The practical version: Victoza stops at 1.8 mg and Saxenda stops at 3 mg. Neither label sets a dose for the other one’s patients.

Both labels print 0.6, 1.2 and 1.8 mg. Those are the same amounts of liraglutide on either label. What changes is where each one sits. 1.2 and 1.8 mg are doses you can stay on with Victoza, and only steps on Saxenda.

The Saxenda dose schedule in full

How long does it take to reach the 1.8 mg dose?

Week 9 at the earliest, from the label’s four-week minimum at each of the 2 steps.

Victoza has 2 steps between the 0.6 mg start and the 1.8 mg ceiling. The label asks for at least four weeks on a dose before the next one. Four weeks at each step is where week 9 comes from.

The label does not print week numbers for Victoza. It gives the first four weeks, and then the four-week rule. Week 9 is that rule applied step by step, not a number quoted off the page.

Week 9 is a floor, not a schedule. Nothing in the label says a person has to keep climbing, and a slower rise is a decision for whoever wrote the prescription.

Can you stay on a low dose of Victoza?

Yes at 1.2 mg, which is the lowest dose this label recognizes as one to stay on.

The label names 1.2 and 1.8 mg as doses to settle on. 1.2 mg is the lowest of those. Below it the label is describing a climb, not a destination.

0.6 mg is printed on the same ladder and is not on that list. The label treats it as somewhere you pass through.

The label sets doses. It does not rank them, and it does not say a higher one suits a given person better.

How does the Victoza ladder compare with every other GLP-1 brand?

Victoza tops out at 1.8 mg once a day. Eight brands in this class stop in eight different places.

The table below compares the approved GLP-1 brands by their highest labeled dose. It is the only place the eight ladders are set out together.

Milligrams do not carry across molecules. 1.8 mg of liraglutide is not comparable to 1.8 mg of anything else. The last column says so on every row where the drug substance differs.

Where two brands do share a drug substance, the comparison is real, because the same molecule is being measured. That is the case for exactly two pairs in the class.

Do the side effects change as the dose goes up?

The label does not publish side effects broken out by dose for Victoza. It reports them across a whole trial.

This is the question the trial tables cannot answer. A label counts how many people reported something over a study, not which dose they were on that week.

The escalation itself is the closest thing to an answer the label gives. It exists because moving up slowly is how the trials were run. The four-week interval is part of the approved schedule, not advice added later.

Where a figure does exist it sits on the side-effect page for this brand. It is taken from the label’s own trial table, with the arm it belongs to.

Where to read next

2 pages sit next to this one, and each answers something this page deliberately does not.

• The liraglutide dosage chart covers the drug rather than the brand, including the vial and syringe arithmetic no pen needs.
• What Victoza costs reads the price off the manufacturer’s own terms rather than the label, including who those terms shut out.